No Scientific Link Found Between Sickle Cell Trait and Sudden Death
Expert panel’s findings refute attribution of sudden death to sickle cell trait (WASHINGTON—Jan. 30, 2025) – A systematic literature review found no evidence to support that physical exertion without rhabdomyolysis (muscle breakdo...
Read moreÎÚÑ»´«Ã½ Announces 2025 Scholar Award Recipients
ASH Scholar Award Celebrates 40 years of funding early-career hematology researchers (WASHINGTON, January 17, 2024) — The ÎÚÑ»´«Ã½ (ASH) announces the 35 recipients of its Scholar Awards for 2025. Now in its 40th ye...
Read moreBelinda Avalos, MD, Begins Term as 2025 ASH President
(WASHINGTON, Jan. 7, 2025) — Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, will serve as president of the ÎÚÑ»´«Ã½ (ASH) for a year-long term through Decemb...
Read moreHeightened Risk of Hospitalization for Blood Clots Seen in People with Long-Term Exposure to Air
Association seen regardless of participants’ smoking status and in those with no prior lung disease (WASHINGTON, Dec. 17, 2024) – People exposed to higher concentrations of three types of air pollution over a period of nearly 17 years ha...
Read moreAdding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma
Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) (SAN D...
Read moreStem Cell Transplant Offers No Additional Benefit for Patients with Mantle Cell Lymphoma in Deep Remission
Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Co...
Read moreUndergoing Stem Cell Transplant for Sickle Cell Disease in Childhood Improves Quality of Life a Decade Later
Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Co...
Read moreGenetic Profile Correlates with Better Response to Treatment for Myeloproliferative Neoplasms
Variants could serve as biomarker to inform prognosis or guide treatment decisions LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (E...
Read moreASH Identifies Strategies and Barriers for Implementing DEI in Clinical Trials
Surveys and focus groups find little integration of DEI principles, yield actionable recommendations (SAN DIEGO, Dec. 9, 2024) — The ÎÚÑ»´«Ã½ (ASH) leveraged its convening power to launch an initiative for identifying ba...
Read moreASH Newborn SCD Screening Program in Sub-Saharan Africa Found Feasible
Program is implementable and scalable despite resource and disease burden challenges (SAN DIEGO, Dec. 8, 2024) — A multi-country newborn screening program for sickle cell disease (SCD) in sub-Saharan Africa proved feasible despite resource cons...
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10